Gene · 5890
Papers1,861
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
281 to 300 of 1,861
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| In Silico Identification and Functional Characterization of Genetic Variations across DLBCL Cell Lines. | Cells | 2023 | 36831263 | PubTator, text mining | PubMed |
| Long-read sequencing identifies novel structural variations in colorectal cancer. | PLoS Genet | 2023 | 36812239 | PubTator, text mining | PubMed |
| DNA repair deficiency as circulating biomarker in prostate cancer. | Front Oncol | 2023 | 36793600 | PubTator, text mining | PubMed |
| Whole-Genome Sequencing Reveals Mutational Signatures Related to Radiation-Induced Sarcomas and DNA-Damage-Repair Pathways. | Mod Pathol | 2023 | 36788076 | PubTator, text mining | PubMed |
| Comparison of the use of prenatal care services and the risk of preterm birth between pregnant women with disabilities and those without disabilities: A nationwide cohort study. | Front Public Health | 2023 | 36778582 | PubTator, text mining | PubMed |
| Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer. | Cancers (Basel) | 2023 | 36765776 | PubTator, text mining | PubMed |
| Follicular Thyroid Adenoma and Follicular Thyroid Carcinoma-A Common or Distinct Background? Loss of Heterozygosity in Comprehensive Microarray Study. | Cancers (Basel) | 2023 | 36765597 | PubTator, text mining | PubMed |
| Relationship between polymorphisms in homologous recombination repair genes RAD51 G172T、XRCC2 & XRCC3 and risk of breast cancer: A meta-analysis. | Front Oncol | 2023 | 36761956 | PubTator, text mining | PubMed |
| AD-Syn-Net: systematic identification of Alzheimer's disease-associated mutation and co-mutation vulnerabilities via deep learning. | Brief Bioinform | 2023 | 36752347 | PubTator, text mining | PubMed |
| Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors. | J Immunother Precis Oncol | 2023 | 36751656 | PubTator, text mining | PubMed |
| Homologous recombination inquiry through ovarian malignancy investigations: JGOG3025 Study. | Cancer Sci | 2023 | 36747324 | PubTator, text mining | PubMed |
| ShrinkCRISPR: a flexible method for differential fitness analysis of CRISPR-Cas9 screen data. | BMC Bioinformatics | 2023 | 36732720 | PubTator, text mining | PubMed |
| Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial. | JCO Precis Oncol | 2023 | 36716415 | PubTator, text mining | PubMed |
| Risk stratification and molecular heterogeneity of endometrial cancer and expression profile of TIM-3: A retrospective cohort study. | Gynecol Oncol | 2023 | 36709662 | PubTator, text mining | PubMed |
| Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance. | EMBO Mol Med | 2023 | 36652375 | PubTator, text mining | PubMed |
| CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. | Nat Commun | 2023 | 36650183 | PubTator, text mining | PubMed |
| CRISPR/Cas9 therapeutics: progress and prospects. | Signal Transduct Target Ther | 2023 | 36646687 | PubTator, text mining | PubMed |
| Genetic variants in African-American and Hispanic patients with breast cancer. | Oncol Lett | 2023 | 36644153 | PubTator, text mining | PubMed |
| Exploring pradimicin-IRD antineoplastic mechanisms and related DNA repair pathways. | Chem Biol Interact | 2023 | 36634904 | PubTator, text mining | PubMed |
| Profiling of the genetic features of Chinese patients with gastric cancer with HRD germline mutations in a large-scale retrospective study. | J Med Genet | 2023 | 36627197 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5890/papers?page=15